CCR7 promotes inhibition of AMPK in human dendritic cells

A novel MEK-ERK-AMPK signalling axis controls chemokine receptor CCR7-dependent survival in human mature dendritic cells*

Pilar López-Cotarelo‡, Cristina Escribano-Díaz‡, Ivan Luis González-Bethencourt‡, Carolina Gómez-Moreira‡, María Laura Deguiz‡, Jesús Torres Bacete‡, Laura Gómez-Cabañas‡, Jaime Fernández-Barrera‡, Cristina Delgado-Martín‡, Mario Mellado§, José Ramón Regueiro‡, María Eugenia Miranda-Carús‡, and José Luis Rodríguez-Fernández†,‡

‡ From CIB/CSIC (Centro de Investigaciones Biológicas. Consejo Superior de Investigaciones Científicas). 28040 Madrid, Spain
§ From CNB/CSIC (Centro Nacional de Biotecnología/Consejo Superior de Investigaciones Científicas.) 28049, Madrid, Spain
† From School of Medicine, Universidad Complutense, Madrid, Spain
‡ From Department of Rheumatology, Hospital La Paz, Madrid, Spain

*Running title: CCR7 promotes inhibition of AMPK in human dendritic cells

To whom correspondence should be addressed: Centro de Investigaciones Biológicas. Consejo Superior de Investigaciones Científicas. C/ Ramiro de Maeztu, 9. 28040 Madrid. Spain. Tel: 34-91-8373112 Ext 4302; FAX 34-34-91-5360436; E-mail: rodrifer@cib.csic.es

Key words: Human / Dendritic Cells / Chemokines / Apoptosis

Background: Chemokine receptor CCR7 promotes survival in mature dendritic cells (mDCs).

Results: Activated AMP-dependent kinase (AMPK) induces apoptosis in mDCs. CCR7 uses the kinases MEK1/2-ERK1/2 to regulate phosphorylation of AMPK on Ser485 and consequently its inhibition.

Conclusion: CCR7 uses a novel MEK1/2-ERK1/2-AMPK signalling axis to induce survival in mDCs.

Significance: AMPK is a potential target to regulate mDC-mediated immune responses.

Abstract

Chemokine receptor CCR7 directs mature dendritic cells (mDCs) to secondary lymph nodes (LNJs) where these cells regulate the activation of T cells. CCR7 also promotes survival in mDCs, which is believed to take place largely through Akt-dependent signalling mechanisms. We have analysed the involvement of the AMP-dependent kinase (AMPK) in the control of CCR7-dependent survival. A pro-apoptotic role for AMPK is suggested by the finding that pharmacological activators induce apoptosis, whereas knocking-down of AMPK with siRNA extends mDCs survival. Pharmacological activation of AMPK also induces apoptosis of mDCs in the LNJs. Stimulation of CCR7 leads to inhibition of AMPK, through phosphorylation of Ser485, which was mediated by Gi/Gp, but not by Akt or S6K, two kinases that control the phosphorylation of AMPK on Ser485 in other settings. Using selective pharmacological inhibitors, we show that CCR7-induced phosphorylation of AMPK on Ser485 is mediated by MEK and ERK. Coimmunoprecipitation analysis and Proximity Ligation Assays (PLA) indicate that AMPK associates with ERK, but not with MEK. The results suggest that in addition to Akt-dependent signalling mechanisms, CCR7 can also promote survival of mDCs through a novel MEK1/2-ERK1/2-AMPK signalling axis. The data also suggest that AMPK may be a potential target to modulate mDC lifespan and the immune response.

Mature dendritic cells (mDCs)§ are potent antigen presenting cells that stimulate naïve T cells in the lymph nodes (1). It has been shown that the longevity of mDCs importantly affects the immune response. In this regard, both mice depleted of mDCs or that present aberrant long lived mDCs, develop autoimmune diseases (2-6). However, between these two extremes, it is observed that the immune response improves as
CCR7 promotes inhibition of AMPK in human dendritic cells

the longevity of the mDCs increases (3,7). The aforementioned results suggest that obtaining information on the mechanisms that regulate mDC survival can be very useful to develop strategies to modulate the longevity of these cells and improve the immune response.

Chemokine receptor CCR7 (ligands CCL19 and CCL21) directs mDCs to the lymph nodes (LNs), attracted first by CCL21, which is expressed in the lymphatic vessels that lead to the LNs, and then by both CCL19 and CCL21, which are both expressed by stromal cells in the LNs (8,9). Apart from directing the migration of mDCs, CCR7 also promotes survival in these cells (10-12), although the signalling mechanisms that regulate the latter function are starting to be defined. Before we showed that CCR7-regulated survival in mDCs is mediated by the Gi family of G proteins and the kinase Akt (10,11). This kinase promotes survival through activation of the transcription factor NFκB and inhibition of several pro-apoptotic targets, including the transcription factors FOXO1/3 and the kinase GSK3β (10-12).

AMPK-dependent kinase (AMPK) is considered a molecular sensor of cellular energy status (13,14). Under conditions of low cellular energy status, AMPK becomes activated, resulting in the stimulation of ATP-consuming (catabolic) pathways and the inhibition of ATP-consuming (anabolic) processes (13,14), which together leads to the recovery of the ATP/ADP ratio of the cell. Recently, it has emerged that AMPK may also promote survival (e.g. (15)) or apoptosis (e.g. (16)) depending on the cell type. AMPK is activated upon phosphorylation of Thr-172, which is located on the activation loop of the catalytic α-subunit of the kinase (17), and it is inhibited by phosphorylation of Ser485/491 (AMPKα1 on Ser485 and AMPKα2 on Ser491) (18-20). Phosphorylation of Ser485/491 blocks the activity of AMPK, even when Thr-172 is phosphorylated, suggesting that phosphorylation of the aforementioned Ser residues exerts a dominant inhibitory role on activity of AMPK (21). It has been shown that the kinases Akt (18,22,23) or S6K (21) can inhibit AMPK by directly phosphorylating Ser485/491 in different cell types. Herein we have studied whether the kinase AMPK plays a role in the regulation of the survival of mDCs. We show, first, that AMPK can play pro-apoptotic roles in mDCs both in vitro and in vivo; second, that the stimulation of CCR7 in mDCs leads to a rapid inhibition of AMPK through the phosphorylation of Ser485, third, that MEK/ERK mediate the CCR7-dependent inhibition of AMPK; fourth, that ERK, but not MEK, interacts with AMPK. Together, the results indicate that CCR7 can contribute to extend the survival of mDCs through the novel MEK1/2-ERK1/2-AMPK signalling axis. The results also suggest that the kinase AMPK may be a potential target to modulate the immune response.

**EXPERIMENTAL PROCEDURES**

**Reagents and Materials**: CCL19, CCL21 and TNFα were from Peprotech (Rocky Hill, NJ). GM-CSF and IL4 were purchased from Immunotools. Fluorescent dye CFSE (carboxyfluorescein diacetate succinimidyl ester) was obtained from Molecular Probes. FLIVO™ is Val-Ala-Asp(OMe)-fluoromethyl ketone (VAD-FMK). Sulforhodamine B (SR)-FLIVO (SR, λabs 565 nm; λem >600 nm), a form of FLIVO conjugated to Sulforhodamine B, was obtained from Immunochrome Technologies, LLC. Z-VAD-FMK was obtained from Enzo (Life Sciences). LY294002, Akt1/2 inhibitor, Pertussis toxin, Hoechst 33342, Propidium iodide and the anti-α-tubulin antibodies were from Sigma. Compound C (24), UO126 and PD0325901, ERK activation inhibitor peptide II, were from Calbiochem (Nottingham, UK). Rapamycin, KU0063794, Gallein, A769662 and FR180204 were obtained from Tocris Bioscience (Bristol, UK). CAY10561 was from Cayman Chemicals (Ann Harbour, MI, USA). The anti-Bim antibody was from Affinity BioReagents (Golden, Colorado, USA). The MEK1, β-actin, 4E-BP1, ERK1, ERK2 and the anti-AMPKα1 antibodies were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). The anti-Akt1, the anti-Bcl-xl, the anti-AMPKα, the anti-TSC2, the anti-mTOR, the anti-phospho-MEK1/2 (Ser217/221), the anti-phospho-ERK1/2 (Thr202/Tyr-204 in ERK1, Thr185/Tyr-187 in ERK2), the anti-phospho-Akt1 (Ser473), the anti-phospho-AMPKα1 (Ser485), the anti-phospho-AMPKα (Thr172), the anti-phospho-TSC2 (T1462), the anti-phospho-mTOR (S2448) and the anti-phospho-4EBP1 (T37/46), the anti-phospho-p70S6K (Thr389), the anti-p70S6K were from Cell Signaling Technology (Beverly, MA). The anti-phospho-acetyl CoA-carboxylase (Ser 79) was from Millipore. The anti-cleave caspase 3 was form BioOrbyt (Cambridge, UK).
CCR7 promotes inhibition of AMPK in human dendritic cells

*Mice*- C57BL/6 mice (8-10 weeks) were maintained in the animal facility at the Centro de Investigaciones Biológicas and treated according to Animal Care Committee guidelines.

Purification of murine DCs and labelling of the cells with fluorescent cell trackers-Murine DCs were purified (97% CD11c+) from spleens of donor mice using magnetic beads (Miltenyi) following the manufacturer’s protocol. DCs used in the *in vivo* studies were labelled for 30 min at 37°C with 2.5 µM of the fluorescent cell tracker probe CFSE in 0.1% BSA in PBS.

**Cells and culture conditions**- Human peripheral blood mononuclear cells (PBMC) were isolated from buffy coats from normal donors over a Lymphoprep (Nycomed, Norway). Monocytes were purified using anti-CD14 magnetic beads (Miltenyi) following the manufacturer’s protocol and then induced to differentiate to DCs by adding GM-CSF and IL4 for 7 days as indicated before (10,11,25-27). The DCs were induced to mature by adding TNFα as indicated before (10,11,25-27).

**Assays of apoptotic damage in vitro**- An equal number of live mDCs (determined by exclusion on trypan blue staining) were incubated in 0.1% BSA or 10% FCS in RPMI in the presence or absence of AMPK activators. Subsequently the mDCs were harvested and plated for 40 min on polyornithine-coated coverslips. Apoptotic nuclear morphology was assessed using Hoechst 33342 staining as indicated before (10,11,25,26) or by analysing the loss of nuclear DNA content by flow cytometry using propidium iodide as indicated elsewhere (28,29).

**Cell lysis and Western blot analysis** - To reduce the basal levels of activity of the molecules analysed, mDCs (100x10^3 cells) were maintained in 0.1% BSA/RPMI for 30 min before starting the stimulation with chemokines. Mature DCs were then stimulated with chemokines for the indicated periods of time. The stimulation was terminated by solubilizing the cells in SDS-PAGE sample buffer (100 mM Tris/HCl, pH 6.8, 0.05 mM sodium orthovanadate, 3% SDS, 1 mM EDTA, 2% 2-mercaptoethanol, 5% glycerol) and boiled. Then fractionated by SDS-PAGE and transferred to nitrocellulose membranes. After blocking with 5% nonfat milk protein in TBST (TBS plus 0.1% Tween 20) pH 7.5, membranes were incubated with the indicated antibodies in TBST and visualised with the appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotecnology) and an ECL substrate (Pierce) detection system. Quantification of the blots was performed using Multigauge software from Fujifilm.

**Immunoprecipitation**- Mature DC (~50x10^6 DCs) were dissolved in lysis buffer A (1% NP-40, 100 mM NaCl, 1 mM EDTA, 0.5 µM of vanadate and 20 mM Hepes pH 7.4, including a protease inhibition cocktail (Sigma, Saint Louise)) and subjected to immunoprecipitation with anti-AMPKα antibody in the presence of TrueBlot anti-rabbit Ig agarose beads (TrueBlot™, eBioscience, San Diego, CA). Immunoprecipitates were washed 5 times in lysis buffer and then boiled in SDS-PAGE sample buffer supplemented with 50 mM dithiothreitol. After SDS-PAGE and transfer to nitrocellulose, the primary antibody step was followed by incubation with a horseradish peroxidase-conjugated antibody that recognizes native rabbit IgG (TrueBlot™, eBioscience, San Diego, CA).

**SiRNAs and nucleofections**- Random control and AMPKα1-siRNAs were obtained from Santa Cruz Biotecnology. The siRNAs were transfected into mDCs by using nucleofection technology (Amaza Biosystems) according to the manufacturer’s instructions.

**Proximity ligation assay (PLA)**. The assay was performed on mDC seeded onto polyornithine-coated coverslips. The mDCs were treated with CCL21 and fixed in 4% PFA. Staining with primary antibodies was performed as in conventional immunofluorescence. However, instead of using fluorescently labeled secondary antibodies, a PLA was carried following manufacturer’s instructions (30) (Duolink II in situ PLA detection kit, Olink Bioscience). Briefly, samples were incubated with secondary antibodies conjugated with DNA probes (MINUS and PLUS DNA probes). Probes were hybridized and ligated, followed by amplification of the DNA template in a rolling circle amplification reaction. A detection solution was added to identify amplified DNA. Finally coverslips with the cells were prepared using mounting medium that includes DAPI to stain the nuclei. The coverslips are analyzed with a confocal microscope and the interaction among ERK and AMPK proteins, detected as distinct fluorescent spots inside each DC, are subsequently quantified.

**Two-photon microscopy and analysis of apoptotic CFSE-dendritic cells in the lymph nodes** The method has been described in detail.
CCRF7 promotes inhibition of AMPK in human dendritic cells

before (10,25,26,31). Briefly, CFSE-labelled splenic mDCs (10^6 mDCs/ml) were dissolved in 20 μl RPMI and injected s.c. along with LPS (1 μg/ml) into the hind footpad of recipient C57BL/6 mice (2x10^6 mDCs per footpad). After 36 h, when the mDCs have already reached the poplitical LN (PLNs) (26,32), treated or control animals were injected intraperitoneally, respectively, with the AMPK activator A769662 (3.6 mg/25 g mice in DMSO) or with vehicle control DMSO. 40.5 h after initiation of the experiment, the mice were injected intravenously with Sulforhodamine B (SR)-FLIVO (SR, λabs 565 nm; λem >600 nm) and after additional 1 h the mice were sacrificed, the poplitical LN extracted from the mice and subsequently subjected to two-photon confocal analysis to visualise among the injected CFSE-mDCs those that present SR-FLIVO staining (see Results). Two-photon microscopy and analysis of apoptotic CFSE-DCs in the LN was performed as described before (31).

Statistics-Data are expressed as mean ± SD, and significance of differences between two series of results was assessed using the Student’s t test. Values of p<0.05 were considered significant and “ns”, indicates non-significant differences.

RESULTS

AMPK promotes apoptosis in mature dendritic cells in vitro. To determine if AMPK could regulate apoptosis in mDCs, we maintained the cells in complete medium in the absence or in the presence of the selective AMPK activators A769662 or AICAR. A769662 is a direct allosteric activator of AMPK [36]. AICAR is an agent that is transported into cells where is phosphorylated to form the AMP-mimetic S-aminoimidazole-4-carboxamida ribonucleoside monophosphate (ZMP), which activates AMPK without altering the intracellular levels of AMP or ATP (33) (Fig. 1A). Western blotting analysis using antibodies that recognize a phosphorylated/active AMPKα (p-AMPK (Thr172)), or phosphorylated acetyl coenzyme A carboxylase (ACC) (p-ACC (Ser 79)), which is a direct target of active AMPK (34), confirmed that the treatment of mDCs with A769662 or AICAR induced activation of AMPK (Fig. 1A(a)). We treated the mDCs with the AMPK activators and then measured the percentage of apoptosis by staining the nuclei of the cells with Hoechst 33342. DCs treated with Akti1/2, a potent inhibitor of the pro-survival kinase Akt (10,11,25), were used as positive controls of apoptosis. As shown in Fig. 1A(b and c), mDCs treated with pharmacological activators of AMPK displayed increased percentage of apoptosis. Similar results were obtained when, instead of Hoechst staining, apoptosis was measured by analysing the loss of nuclear DNA content typical of apoptotic cells by flow cytometry using propidium iodide as label (28,29) (Fig. 1A(d)) or the activation of caspase-3, another well-known apoptotic marker (Fig. 1A(e)). When the pharmacological activators of AMPK were used to induce apoptosis in mDCs that had been pre-treated with Z-VAD-FMK, a general caspase inhibitor, the effects of the AMPK activators on the apoptosis of the cells were abrogated, indicating that these agents induce caspase-dependent cell death (Fig. 1B). Finally, to corroborate that AMPK played pro-apoptotic roles in DCs, we reduced AMPK levels using siRNA (Fig. 1C(a)). When DCs with normal or reduced levels of AMPK were shifted to 0.1%BSA/RPMI for 24 h and then stained with Hoechst 33342, it was observed that the mDCs that displayed reduced levels of AMPK (Fig. 1C(b)) presented also a reduced percentage of apoptosis. Together the results indicate that AMPK can promote apoptosis in mDCs.

We analysed potential mechanisms whereby active AMPK could induce apoptosis in DCs. Before we have reported that the kinase GSK3β may induce apoptosis in DCs by promoting the translocation to the nucleus of the transcription factor FOXO (10), which controls the expression of the pro-apoptotic Bcl2 family member Bim (10,25,26,35). We tested whether similarly active AMPK could also promote the translocation of FOXO and induce overexpression of Bim in DCs. For this purpose, we transfected the DCs with FOXO1-GFP and then induced activation of AMPK by stimulating the DCs with AICAR or A769662. As shown in Fig. 2A, these agents induced a significant increase in the number of DCs that displayed FOXO-GFP in the nucleus. Consistent with these results, the stimulation of DCs with AICAR or A769662 also caused an increase in Bim levels in the DCs (Fig. 2B). In similar experiments we did not observed any change in the expression of the pro-survival Bcl2 member Bclcl (not shown). Together these results suggest that AMPK could induce apoptosis in DCs by promoting translocation of pro-apoptotic
CCR7 promotes inhibition of AMPK in human dendritic cells

FOXO1 to the nucleus, which up-regulates the expression of the pro-apoptotic Bim.

Since it has been shown that AMPK inhibits the kinase complex mTORC1 (36,37), and mTORC1 has been shown to mediate the pro-survival signalling of the kinase Akt (38), we hypothesised that active AMPK may induce apoptosis by interfering with the pro-survival signalling induced from mTORC1 in DCs. To test this concept first, we analysed whether mTORC1 plays a pro-survival role in DCs. Inhibition mTORC1 by treating the DCs with the highly selective inhibitor Rapa, induces apoptosis, indicating that mTORC1 promotes survival in these cells (Fig. 2C). Next we studied whether CCR7 could also induce activation of mTORC1. As shown in Fig 2D, stimulation of CCR7 with CCL21 induces phosphorylation/inhibition of the mTORC upstream inhibitory molecule TSC2 and an increase in the phosphorylation of 4EBP1, a direct downstream target of mTORC (Fig. 2D), together indicating that CCR7 induces activation of mTORC1. Finally, we analysed whether active AMPK could inhibits CCR7-dependent activation of mTORC1 (Fig. 2E). The treatment of the DCs with A769662 or AICAR which, as indicated by the elevated levels of active/phosphorylated AMPK (Thr172), induced activation of AMPK (Fig. 2E), also inhibited mTORC1 activity, as indicated by the reduction in the phosphorylation of 4EBP1 (Fig. 2E). Together the results indicate that in DCs active AMPK may also promote apoptosis by inhibiting mTORC1.

Stimulation of CCR7 receptor induces phosphorylation / inhibition of AMPK. As we have shown before that stimulation of CCR7 protects mDCs from apoptosis (10,11), we hypothesised that this receptor could also induce inhibition of pro-apoptotic AMPK in these cells. To test this hypothesis, the mDCs were treated with CCL21 for various times and then lysed in sample buffer. Subsequently, we examined the activity of AMPK using an antibody that recognizes the phosphorylated/inactive form of AMPKα1 (p-Ser485). Stimulation with CCL21 (Fig. 3A) or CCL19 (not shown) induced inactivation of AMPK, which remained at relatively high levels until 60 min and only decayed after 120 min (Fig. 3A). Consistent with these results, stimulation of CCR7 caused also a reduction of the phosphorylation of the AMPK substrate ACC (Fig. 3B). When we used an antibody that recognizes the active form of AMPK (p-Thr172), it was observed that stimulation of CCR7 also led to reduced levels of this active form of AMPK (Fig. 3B). Finally, the treatments of the mDCs with compound C, a selective inhibitor of AMPK (24), blunted, the phosphorylation of the active form of AMPK (p-Thr172) (Fig. 3C(a)), but failed to affect the CCR7-induced phosphorylation of Ser485 on AMPK (Fig. 3C(b)). Since AMPK activity is completely blunted after the treatment with compound C, the results indicate that upon stimulation of CCR7 the phosphorylation of AMPK on Ser485 was not due to an autophosphorylation event, but to the activity of an upstream kinase. In summary, the experiments indicate that stimulation of CCR7 in mDC causes phosphorylation on Ser485 and inhibition of AMPK, which is mediated by an upstream kinase.

Activation of AMPK induces apoptosis of murine DCs in the lymph nodes. We studied whether active AMPK could also play a pro-apoptotic role in the lymph node (LNs), the setting where DCs present antigens to naïve T-cells during the initiation of the immune response. Before performing the experiment in vivo, we first analysed if the treatment with AMPK activators induced also apoptosis in the splenic mDCs in vitro. Treatment with AICAR and A769662 enhanced significantly the activity of AMPK (Fig. 4A(a)) and the apoptosis of the cells (Fig. 4A(b)), indicating that active AMPK is also pro-apoptotic in splenic mDCs in culture. Furthermore, stimulation of splenic mDCs with murine CCL19 or CCL21 also induced, like in human mDCs, phosphorylation of AMPK on Ser485 (Fig. 4B).

As it is known that conventional mDCs that arrive from peripheral tissues to the LNs become largely apoptotic in these regions (26,39), we studied if activators of AMPK could enhance the percentage of apoptotic mDCs inside the popliteal LNs (PLNs), which would indicate that active AMPK plays pro-apoptotic roles in these cells in vivo. For this purpose, C57BL/6 mice were injected subcutaneously in the hind footpad with carboxyfluorescein diacetate succinimidyl ester (CFSE)-labeled splenic DCs. After 36 h, a time at which, as shown by us before (26), there is a significant number of CFSE-labeled DCs positioned in the PLNs, the mice were injected intraperitoneally with 100 μmoles of A769662. Control animals were injected with the same
amount of vehicle (Fig. 4C(a)). After additional 4.5 h, the animals were injected intravenously with SR-FLIVO, a poly caspase binding inhibitor probe \([\text{Val-Ala-Asp(OMe)-}\text{fluoromethyl ketone (VAD-FMK)}]\) conjugated to a fluorescent dye that binds irreversibly to apoptotic caspases and allows the detection of apoptotic cells in vivo \((10,25,26,31)\). One hour after the injection of SR-FLIVO, the mice were sacrificed, the PLNs were obtained and analysed by two-photon microscopy. In these experiments it would be expected, if AMPK is pro-apoptotic, an enhanced SR-FLIVO staining in the mDCs in the PLNs obtained from the A769662-treated animals compared to the vehicle-treated controls. Consistent with this prediction, mice injected with A769662 displayed a significant increase in the percentage of SR-FLIVO-labelled CFSE-DCs, indicating that active AMPK plays pro-apoptotic roles in the mDCs in vivo (Fig. 4C(b and c)). We also observed induction of apoptosis in the DCs inside the PLNs when the mice were injected with AICAR (not shown). In summary, the prior experiments indicate that active AMPK promotes apoptosis of mDCs both in vivo and in vitro.

**CCR7-dependent inhibition of AMPK in mDCs is mediated by G\(_i\) and G\(_{\beta\gamma}\), but not by PI3K/Akt or S6K.** In the next experiments we studied the signalling pathway that could regulate downstream of CCR7, the phosphorylation/inhibition of AMPK. As the G\(_i\) protein family of G proteins, and the G\(_{\beta\gamma}\) dimers associated to these proteins, mediate CCR7-dependent survival in mDCs \((10,11)\), we tested their involvement in the control of CCR7-dependent inhibition of AMPK. Gi-mediated signalling was blocked by treating the mDCs with the selective inhibitor pertussis toxin (PTX) and G\(_{\beta\gamma}\)-mediated signalling was blocked by treating the cells with Gallein \((40)\). The observed inhibition of the CCR7-dependent phosphorylation of ERK1/2 (Fig 5A(a) and (b)), two kinases known to be regulated by Gi and G\(_{\beta\gamma}\) \((10,27)\), indicated that both PTX and Gallein blocked efficiently their targets. The treatment with PTX or Gallein also blunted the CCR7-induced phosphorylation of AMPK on Ser485 (Fig. 5A(a) and (b)), indicating that Gi and G\(_{\beta\gamma}\) regulate downstream of CCR7 the phosphorylation of AMPK on Ser485.

Stimulation of CCR7 induces activation of Akt in mDCs \((10,11,41)\) which is also controlled by the Gi family of proteins \((10,11)\). As Akt mediates the phosphorylation of Ser485 on AMPK in a variety of cell types \((18,22,23,42)\), we analysed whether it could also play a similar role downstream of CCR7 in mDCs. Surprisingly, the blocking of the activity of Akt, with the PI3K inhibitor LY294002 (Fig 5B(a)) or with the selective Akt inhibitor Akti1/2 \((43)\) (Fig. 5B(b)) failed to affect CCR7-dependent phosphorylation of AMPK on Ser485, indicating that Akt does not mediate CCR7-dependent inhibition of AMPK in mDCs. Further emphasizing that Akt and AMPK are independently regulated, the inhibition of AMPK, by treating the mDCs with Compound C, did not affect the CCR7-dependent phosphorylation of Akt (not shown).

Stimulation of CCR7 also induces activation of the mammalian target of rapamycin complex 1 (mTORC1) (Fig. 5C), which promotes survival in mDCs (unpublished results). Recently, it has been shown that S6K, a molecule that is regulated by mTORC1 \((44)\), may also directly phosphorylate AMPK on Ser485 \((21)\). Therefore, we studied whether inhibition of S6K could block CCR7-dependent phosphorylation of AMPK on Ser485. To inhibit S6K we treated the mDCs with pharmacological agents that block either Akt (Akti) or mTORC1 (Rapa or KU0063794), both upstream regulators of S6K \((44)\) (Fig 5D). To analyse S6K activity we used an antibody that recognizes a phosphorylated/active form of this kinase (p-S6K (Thr389)). Treatment of the mDCs with the inhibitors Akti1/2 \((43)\), Rapamycin \((43,45)\) and Ku \((46)\), to inhibit Akt, mTORC1 and mTORC1/2, respectively, blunted, as expected, the activation of S6K. However, despite strong inhibition of S6K, the CCR7-dependent phosphorylation of AMPK on Ser485 was not affected (Fig. 5D). The results indicate that Akt, mTORC1, mTORC2 or S6K do not mediate CCR7-dependent inhibition of AMPK in mDCs (see model in Fig. 9).

**CCR7-dependent inhibition of AMPK in DCs is mediated by MEK/ERK.** Upon stimulation of the mDCs with CCL21, we observed similar kinetics in the activation of the kinases MEK1/2/ERK1/2 and phosphorylation of AMPK on Ser485 (Fig. 6A). Therefore, we studied whether downstream of CCR7, MEK1/2/ERK1/2 could mediate the phosphorylation of AMPK on Ser485. Treatment of the cells with U0126 (Fig. 6B) or PD03255901 (Fig. 6C), two potent and selective inhibitors of MEK1/2 \((45)\) and, consequently of
ERK1/2, the only known downstream targets of MEK1/2 (47), blunted CCR7-dependent phosphorylation of AMPK, indicating that MEK1/2 regulates downstream of CCR7 the phosphorylation of AMPK on Ser485. In the next experiments we studied whether ERK1/2 could also regulate AMPK phosphorylation on Ser485. Our attempts to reduce the expression of ERK1 or ERK2 in mDC using siRNAs were unsuccessful. Although the siRNAs used readily blunted ERK1 and ERK2 expression in HL-60 cells, we were unable to reduce the levels of these two kinases in mDCs (not shown). Therefore, we decided to use two pharmacological inhibitors to block ERK1/2 activity, namely, CAY10561 (Fig. 7A) or FR180204 (Fig. 7B). CAY10561 displays a high selectivity against ERK when tested against a panel of 184 (48,49), and FR180 against 8 related kinases (50). As shown in Fig. 7A and B, although the effects of CAY10561 and FR180 displayed higher variability when compared to the effects of the MEK1/2 inhibitors; however, both agents blocked CCR7-dependent phosphorylation of AMPKα on Ser485. Therefore, the results indicate that ERK1/2 can mediate the effects of MEK1/2 to induce inhibition of AMPK. As the pharmacological blocking of MEK1/2 and ERK1/2 prevents the phosphorylation/inhibition of AMPK, which plays pro-apoptotic roles, we predicted that treatment of the mDCs with the inhibitor would reduce the pro-survival effects induced by stimulation of CCR7. As shown in Fig. 7C, as expected, the pre-treatment of the mDCs with the inhibitors of MEK1/2 or ERK1/2, reduced the pro-survival effects induced by the stimulation of CCR7, although at an extent slightly lower than that induced by inhibition of Akt.

ERK associates to AMPK. As downstream of CCR7 active MEK/ERK are required to observe phosphorylation of AMPK on Ser485, we studied the possibility that these molecules could associate to AMPKα in mDCs. We immunoprecipitated the endogenous AMPKα from cultures of mDCs and then carried out a western blotting to analyze for the presence of ERK1 or MEK1 in the immunoprecipitates. As shown in the Fig. 8A, we observed that AMPKα and ERK1 interacted both in unstimulated or CCL21-stimulated mDCs, suggesting that these two proteins are able to associate, directly or indirectly, constitutively. In contrast, we did not detect MEK1 in the AMPKα immunoprecipitates (not shown). Since direct or indirect protein-protein associations cannot be discriminated by immunoprecipitation, to study whether AMPKα and ERK1 could interact directly each other, we performed a Proximity Ligation Assay (PLA) (51,52). This is a novel microscopy technique that allows detecting with high specificity and sensitivity close proximity between two proteins (<40 nm), suggesting direct interactions between these two molecules (30,51,52). The mDCs were plated on polyornithine-coated dishes, then they were stimulated with CCL21 and finally they were subjected to a PLA analysis. Negative controls where single antibodies against ERK1 (Fig 8B(a)), AMPKα (Fig 8B(a)) or MEK1 (Fig 8B(b)) were used, showed no PLA fluorescence. Interestingly, we observed PLA fluorescence signal between the pair ERK1/AMPKα, only in CCL21-stimulated mDCs, but not in unstimulated mDCs, suggesting that stimulation of CCR7 induces proximity between these two kinases (Fig 8B(c)). Consistent with immunoprecipitation results, we did not observe PLA fluorescent signal between the pair MEK1/AMPKα (not shown). Analysis of the interaction between ERK1 and MEK1, which was used as a positive control, showed also intense PLA fluorescence in the stimulated, but not in the unstimulated mDCs (Fig 8B(d)). In summary, the results show that ERK and AMPK may be part of a similar protein complex and in this complex active ERK may control the phosphorylation of AMPK on Ser485.

DISCUSSION
CCR7 directs mDCs to the LNs where the initiation of the immune response takes place. Before we have shown that in addition to chemotaxis, CCR7 can promote survival in mDCs through the kinase Akt (10-12), which controls survival by inducing activation of NFκB and inhibition of FOXO1/3 and GSK3β (10-12). To get further insights on the mechanisms used by CCR7 to induce survival in mDCs, herein we have analyzed the involvement of the kinase AMPK in this process. Our results indicate that in mDCs AMPK can play pro-apoptotic roles in vitro and in vivo.

The phenotypical features presented by the DCs that die after inducing activation of AMPK suggest that this kinase may induce an apoptotic type of death. In this regard, AMPK-dependent death is inhibited by the pan-caspase inhibitor z-
VAD-FMK, it associates to caspase 3 activation, to the fragmentation of the nucleus and to the increase in the expression of the pro-apoptotic Bcl2 family member Bim. Our results indicate that AMPK may promote apoptosis, at least partially, by inducing translocation to the nucleus of FOXO1, a transcription factor that plays pro-apoptotic roles in mDCs through the regulation of the expression of Bim (10,25,26), and by inhibiting mTORC1, a kinase complex controlled by CCR7 that also induces survival in mDCs (10,26). In other cell types AMPK has also been shown to be able to promote apoptosis using these two mechanisms (36,53,54).

Consistent with its pro-survival role of the chemokine receptor CCR7 (11), we observed that its stimulation induces a rapid phosphorylation/inhibition of pro-apoptotic AMPK on Ser485 (18-21). This inhibition of AMPK may promote DC survival through the effects that can be exerted on FOXO and mTORC1. Before we showed that stimulation of CCR7 induces activation of Akt which, upon phosphorylating nuclear FOXO, induces its translocation to the cytoplasm (10,11), preventing this factor from exerting pro-apoptotic effects through Bim. However, in contrast to Akt, active AMPK promotes, as shown above, the translocation of FOXO to the nucleus of DCs, from where it can regulate apoptosis. Thus, CCR7-mediated inhibition of AMPK, prevents that this kinase may oppose the effects of Akt on FOXO, facilitating the complete translocation of FOXO to the cytoplasm. Moreover, CCR7-dependent inhibition of AMPK can also prevent that this kinase may inhibit the pro-survival effects exerted by mTORC1. Thus, CCR7-mediated inhibition of AMPK can contribute to the extended survival of the DCs.

The results suggest that downstream of CCR7 the kinases MEK/ERK, but not Akt or S6K, mediates the phosphorylation of AMPK on Ser485. Our results also indicate that ERK and AMPK may be components of a signaling complex where active ERK controls the phosphorylation of AMPK on Ser485. Interestingly, these data contrast with prior results, obtained in other cells types, where it has been indicated that AMPK promotes inhibition of ERK (55-58), pointing out context dependent differences in the mechanism used by these two molecules to regulate each other. Previously it has also been shown that infection of PK-15 cells with Porcine circovirus type 2 (PCV2) also promotes interaction between AMPK and ERK (58). To the best of our knowledge our work is the first report indicating that MEK/ERK can mediate the inhibition of AMPK by regulating Ser485 phosphorylation.

The results obtained also indicate that MEK/ERK can regulate mDC survival. Until now we had overlooked a role for MEK/ERK as regulators of CCR7-dependent survival in mDCs probably due to the relatively less important role of these kinases as regulators of this function compared to Akt. In most early experiments, the effects of MEK/ERK on mDC survival were analysed after relatively short periods (6-10 h). Under these conditions the effects of interfering with MEK/ERK on survival were negligible when compared to that induced by Akt inhibition. Only when apoptosis was analysed after longer treatment with ERK1/2 inhibitors (24-40 h), MEK/ERK emerge as a regulator of mDC survival, although still less potent than Akt. In Fig 9, we present a model that summarizes the results obtained regarding the signalling mechanisms involved in the phosphorylation / inhibition of AMPK.

The results indicating that MEK/ERK, but not Akt, control AMPK phosphorylation on Ser485 were unexpected for several reasons. First, we have shown before that Akt is a key mediator of CCR7-dependent survival in mDCs (10,11). Second, CCR7-mediated activation of Akt and phosphorylation of AMPK on Ser485 were both mediated by Gi, suggesting that the CCR7-Gi-Akt axis may regulate the phosphorylation of AMPK. Third, Akt inhibits AMPK by directly phosphorylating Ser485 on AMPK in several other cell types (18,22,23,42). However, despite these prior results, we observe that inhibition of Akt or S6K, another kinase involved recently in the regulation of the phosphorylation of AMPK on Ser485 (21), failed to block the phosphorylation of this residue upon stimulation of CCR7. In contrast, inhibition of MEK or its direct target ERK, blocked CCR7-dependent phosphorylation of AMPK on Ser485. Therefore, MEK/ERK emerge as novel regulators of the phosphorylation/inhibition of AMPK and, consequently the survival of mDCs in addition to Akt. Interestingly MEK-ERK dependent phosphorylation of AMPK on Ser485, seems cell and/or receptor-specific because in granulosa cells, MEK/ERK inhibition was ineffective to prevent the follicle-stimulating hormone (FSH)-mediated phosphorylation of AMPK on Ser485.
CCR7 promotes inhibition of AMPK in human dendritic cells

(22). These disparate results regarding the roles of Akt, S6K and MEK/ERK on the phosphorylation of Ser485 emphasize the combinatorial character of the signalling pathways and the importance of a detailed knowledge of the specific pathways used by specific receptors in each cell type. In summary, the data presented herein indicate that CCR7 may use the MEK-AMPK axis, in addition to Akt-dependent mechanisms (10-12), to promote survival in mDCs. These results add a novel component to the array of signals relayed from CCR7 to promote the survival of mDCs and provide new potential targets to modulate the function of these cells in the immune system.

Acknowledgements. We acknowledge P. Lastres for help with the cytometer and discussions, Génesis Andrea Altuve Urbina and Cristina Ruano Domínguez for expert technical assistance. We acknowledge Jill Suttles (University of Louisville School of Medicine) for her kindly supplying of reagents.

REFERENCE
1. Ueno, H., Klechevsky, E., Morita, R., Aspord, C., T. Cao, T., Matsui, T., Di Pucchio, T., Connolly, J., Fay, J. W., Pascual, V., Palucka, A. K., and Banchereau, J. (2007) Dendritic cell subsets in health and disease. *Immunol Rev.* **219**, 118-142
2. Chen, M., Huang, L., and J., W. (2007) Deficiency of Bim in dendritic cells contributes to overactivation of lymphocytes and autoimmunity. *Blood* **109**, 4360-4367
3. Hildeman, D., Jorgensen, T., Kappler, J., and Marrack, P. (2007) Apoptosis and the homeostatic control of immune responses. *Curr. Opin. Immunol.* **19**, 516-521
4. Hou, W. S., and Van Parijs, L. (2004) A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. *Nat. Immunol.* **5**, 583-589
5. Nopora, A., and Brocker, T. (2002) Bcl-2 controls dendritic cell longevity in vivo. *J. Immunol.* **169**, 3006-3014
6. Ohnmacht, C., Pullner, A., King, S. B., Drexler, I., Meier, S., Brocker, T., and Voehringer, D. (2009) Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity. *J Exp Med.* **206**, 549-559
7. Kushwah, R., and Hu, J. (2010) Dendritic cell apoptosis: regulation of tolerance versus immunity. *J. Immunol.* **185**, 795-782
8. Randolph, G. J., J. Ochando, J., and Partida-Sánchez, S. (2008) Migration of dendritic cell subsets and their precursors. *Annu Rev Immunol.* **26**, 293-316
9. Comerford, I., Harata-Lee, Y., Bunting, M. D., Gregor, C., Kara, E. E., and McColl, S. R. (2013) A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system. *Cytokine Growth Factor Rev.* **24**, 269-283
10. Escribano, C., Delgado-Martin, C., and Rodriguez-Fernandez, J. L. (2009) CCR7-dependent stimulation of survival in dendritic cells involves inhibition of GSK3beta. *J Immunol* **183**, 6282-6295
11. Sanchez-Sanchez, N., Riol-Blanco, L., de la Rosa, G., Puig-Kroger, A., Garcia-Bordas, J., Martin, D., Longo, N., Cuadrado, A., Cabanas, C., Corbi, A. L., Sanchez-Mateos, P., and Rodriguez-Fernandez, J. L. (2004) Chemokine receptor CCR7 induces intracellular signaling that inhibits apoptosis of mature dendritic cells. *Blood* **104**, 619-625
12. Sanchez-Sanchez, N., Riol-Blanco, L., and Rodriguez-Fernandez, J. L. (2006) The multiple personalities of the chemokine receptor CCR7 in dendritic cells. *J Immunol* **176**, 5153-5159
13. Hardie, D. G. (2011) AMP-activated protein kinase—an energy sensor that regulates all aspects of cell function. *Genes Dev.* **25**, 1895-1908
14. Hardie, D. G., Ross, F. A., and Hawley, S. A. (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. *Nat. Rev. Mol. Cell. Biol.* **13**, 251-262
CCR7 promotes inhibition of AMPK in human dendritic cells

15. Ido, Y., Carling, D., and Ruderman, N. (2002) Hyperglycemia-Induced Apoptosis in Human Umbilical Vein Endothelial Cells. Inhibition by the AMP-Activated Protein Kinase Activation. *Diabetes* **51**, 159-167

16. Campas, C., Lopez, J. M., Santidrián, A. F., Barragán, M., Bellosillo, B., Colomer, D., and Gil, J. (2003) Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes. *Blood* **101**, 3674-3680

17. Woods, A., Vertommen, D., Neumann, D., Turk, R., Bayliss, J., Schlattner, U., Wallimann, T., Carling, D., and Rider, M. H. (2003) Identification of phosphorylation sites in AMP-activated protein kinase (AMPK) for upstream AMPK kinases and study of their roles by site-directed mutagenesis. *J. Biol. Chem.* **278**, 28434-28442

18. Hormon, S., Vertommen, D., Heath, R., Neumann, D., Mouton, V., Woods, A., Schlattner, U., Wallimann, T., Carling, D., Hue, L., and M.H., R. (2006) Insulin antagonizes ischemia-induced Thr172 phosphorylation of AMP-activated protein kinase alpha-subunits in heart via hierarchical phosphorylation of Ser485/491. *J. Biol. Chem.* **281**, 5335–5340

19. Hurley, R. L., Barré, L. K., Wood, S. D., Anderson, K. A., Kemp, B. E., Means, A. R., and Witters, L. A. (2006) Regulation of AMP-activated protein kinase by multisite phosphorylation in response to agents that elevate cellular cAMP. *J Biol Chem.* **281**, 36662-36672

20. Pulinilkunnil, T., He, H., Kong, D., Asakura, K., Peroni, O. D., Lee, A., and Kahn, B. B. (2011) Adrenergic regulation of AMP-activated protein kinase in brown adipose tissue in vivo. *J Biol Chem.* **286**, 8798-9809

21. Dagon, Y., Hur, E., Zheng, B., Wellenstein, K., Cantley, L. C., and Kahn, B. B. (2012) p70S6 kinase phosphorylates AMPK on serine 491 to mediate leptin's effect on food intake. *Cell Metab.* **16**, 104-112

22. Kayampilly, P. P., and Menon, K. M. (2009) Follicle-stimulating hormone inhibits adenosine 5'-monophosphate-activated protein kinase activation and promotes cell proliferation of primary granulosa cells in culture via an Akt-dependent pathway. *Endocrinology* **150**, 929-935

23. Kovacic, S., Soltys, C. L., Barr, A. J., Shiojima, I., Walsh, K., and Dyck, J. R. (2003) Akt activity negatively regulates phosphorylation of AMP-activated protein kinase in the heart. *J. Biol. Chem.* **278**, 39422–39427

24. Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Dobbber, T., Fuji, N., Musi, N., Hirshman, M. F., Goodyear, L. J., and Moller, D. E. (2001) Role of AMP-activated protein kinase in mechanism of metformin action. *J Clin Invest.* **108**, 1167-1174

25. Delgado-Martín, C., Escribano, C., Pablos, J. L., Riol-Blanco, L., and Rodriguez-Fernandez, J. L. (2011) Chemokine CXCL12 uses CXCR4 and a signaling core formed by bifunctional Akt, extracellular signal-regulated kinase (ERK)1/2, and mammalian target of rapamycin complex 1 (mTORC1) proteins to control chemotaxis and survival simultaneously in mature dendritic cells. *J Biol Chem* **286**, 37222-37236

26. Riol-Blanco, L., Delgado-Martín, C., Sanchez-Sanchez, N., Alonso-C, L. M., Gutierrez-Lopez, M. D., Del Hoyo, G. M., Navarro, J., Sanchez-Madrid, F., Cabanas, C., Sanchez-Mateos, P., and Rodriguez-Fernandez, J. L. (2009) Immunological synapse formation inhibits, via NF-kappaB and FOXO1, the apoptosis of dendritic cells. *Nat Immunol* **10**, 753-760

27. Riol-Blanco, L., Sanchez-Sanchez, N., Torres, A., Tejedor, A., Narumiya, S., Corbi, A. L., Sanchez-Mateos, P., and Rodriguez-Fernandez, J. L. (2005) The chemokine receptor CCR7 activates in dendritic cells two signaling modules that independently regulate chemotaxis and migratory speed. *J Immunol* **174**, 4070-4080

28. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. *J Immunol Methods* **139**, 271-279

29. Riccardi, C., and Nicoletti, I. (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. *Nat Protoc* **1**, 1458-1461
CCR7 promotes inhibition of AMPK in human dendritic cells

30. Soderberg, O., Gullberg, M., Jarvis, M., Ridderstrale, K., Leuchowius, K. J., Jarvis, J., Wester, K., Hydbring, P., Bahram, F., Larsson, L. G., and Landegren, U. (2006) Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 3, 995-1000
31. Gomez-Cabanas, L., Delgado-Martin, C., Lopez-Cotarelo, P., Escribano-Diaz, C., Alonso, C. L., Rioi-Blanco, L., and Rodriguez-Fernandez, J. L. (2014) Detecting apoptosis of leukocytes in mouse lymph nodes. Nat Protoc 9, 1102-1112
32. Mempel, T. R., Henrickson, S. E., and von Andrian, U. H. (2004) T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases. Nature 427, 154-159
33. Corton, J. M., Gillespie, J. G., Hawley, S. A., and Hardie, D. G. (1995) 5-aminoimidazole-4-carboxamidine ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565
34. Winder, W. W., and Hardie, D. G. (1996) Inactivation of acetyl-CoA carboxylase and activation of AMP-activated protein kinase in muscle during exercise. Am. J. Physiol. Endocrinol. Metab. 270, E299-E304
35. Gilley, J., Coffer, P. J., and Ham, J. (2003) FOXO transcription factors directly activate bim gene expression and promote apoptosis in sympathetic neurons. J Cell Biol 162, 613-622
36. Inoki, K., Zhu, T., and Guan, K. L. (2003) TSC2 mediates cellular energy response to control cell growth and survival. Cell 115, 577-590
37. Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., and Shaw, R. J. (2008) AMPK phosphorylation of raptor mediates a metabolic checkpoint. Mol Cell 30, 214-226
38. Hung, C. M., Garcia-Haro, L., Sparks, C. A., and Guertin, D. A. (2012) mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol 4, a008771
39. Kamath, A. T., Henri, S., Battye, F., Tough, D. F., and Shortman, K. (2002) Developmental kinetics and lifespan of dendritic cells in mouse lymphoid organs. Blood 100, 1734-1741
40. Lehmann, D. M., Seneviratne, A. M., and Smrcka, A. V. (2008) Small molecule disruption of G protein beta gamma subunit signaling inhibits neutrophil chemotaxis and inflammation. Mol Pharmaco. 73, 410-418
41. Iijima, N., Yanagawa, Y., Clingan, J. M., and Onoe, K. (2005) CCR7-mediated c-Jun N-terminal kinase activation regulates cell migration in mature dendritic cells. Int Immunol 17, 1201-1212
42. Beauloye, C., Marsin, A. S., Bertrand, L., Krause, U., Hardie, D. G., Vanoverschelde, J. L., and Hue, L. (2001) Insulin antagonizes AMP-activated protein kinase activation by ischemia or anoxia in rat hearts, without affecting total adenine nucleotides. FEBS Lett 505, 348-352
43. Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C. J., McLauchlan, H., Klevernic, I., Arthur, J. S., Alessi, D. R., and Cohen, P. (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408, 294-315
44. Foster, K. G., and Fingar, D. C. (2010) Mammalian target of Rapamycin (mTOR): Conducing the cellular signaling symphony. J. Biol. Chem. 285, 14071-14077
45. Davies, S. P., Reddy, H., Caivano, M., and Cohen, P. (2000) Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 351, 95-105
46. Garcia-Martinez, J. M., Moran, J., Clarke, R. G., Gray, A., Cosulich, S. C., Chresta, C. M., and Alessi, D. R. (2009) Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem J 421, 29-42
47. Kolch, W. (2005) Coordinating ERK/MAPK signalling through scaffolds and inhibitors. Nat Rev Mol Cell Biol 6, 827-837
48. Aronov, A. M., Baker, C., Bemis, G. W., Cao, J., Chen, G., Ford, P. J., Germann, U. A., Green, J., Hale, M. R., Jacobs, M., Janetka, J. W., Maltais, F., Martinez-Botella, G., Namchuk, M. N., Straub, J., Tang, Q., and Xie, X. (2007) Flipped out: structure-guided design of selective pyrazolylpyrrole ERK inhibitors. J Med Chem 50, 1280-1287
CCR7 promotes inhibition of AMPK in human dendritic cells

49. Hatzivassiliou, G., Liu, B., O’Brien, C., Spoerke, J. M., Hoeflich, K. P., Haverty, P. M., Soriano, R., Forrest, W. F., Heldens, S., Chen, H., Toy, K., Ha, C., Zhou, W., Song, K., Friedman, L. S., Amler, L. C., Hampton, G. M., Moffat, J., Belvin, M., and Lackner, M. R. (2012) ERK inhibition overcomes acquired resistance to MEK inhibitors. Mol Cancer Ther 11, 1143-1154

50. Ohori, M., Kinoshita, T., Okubo, M., Sato, K., Yamazaki, A., Arakawa, H., Nishimura, S., Inamura, N., Nakajima, H., Neya, M., Miyake, H., and Fujii, T. (2005) Identification of a selective ERK inhibitor and structural determination of the inhibitor-ERK2 complex. Biochem Biophys Res Commun 336, 357-363

51. Fredriksson, S., Gullberg, M., Jarvius, J., Olsson, C., Pietras, K., Gustafsdottir, S. M., Ostman, A., and Landegren, U. (2002) Protein detection using proximity-dependent DNA ligation assays. Nat Biotechnol. 20, 473-477

52. Weibrecht, I., Leuchowius, K. J., Claussson, C. M., Conze, T., Jarvius, M., Howell, W. M., Kamali-Moghaddam, M., and Söderberg, O. (2010) Proximity ligation assays: a recent addition to the proteomics toolbox. Expert Rev Proteomics 7, 401-409

53. Greer, E. L., Oskoui, P. R., Banko, M. R., Maniar, J. M., Gygi, M. P., Gygi, S. P., and Brunet, A. (2007) The energy sensor AMP-activated protein kinase directly regulates the mammalian FOXO3 transcription factor. J Biol Chem 282, 30107-30119

54. Mihaylova, M. M., and Shaw, R. J. (2011) The AMPK signalling pathway coordinates cell growth, autophagy and metabolism. Nat Cell Biol 13, 1016-1023

55. Du, J., Guan, T., Zhang, H., Xia, Y., Liu, F., and Zhang, Y. (2008) Inhibitory crosstalk between ERK and AMPK in the growth and proliferation of cardiac fibroblasts. Biochem Biophys Res Commun 368, 402-407

56. Hwang, S. L., Jeong, Y. T., Li, X., Kim, Y. D., Lu, Y., Chang, Y. C., Lee, I. K., and Chang, H. W. (2013) Inhibitory cross-talk between the AMPK and ERK pathways mediates endoplasmic reticulum stress-induced insulin resistance in skeletal muscle. Br J Pharmacol 169, 69-81

57. Shen, C. H., Yuan, P., Perez-Lorenzo, R., Zhang, Y., Lee, S. X., Ou, Y., Asara, J. M., Cantley, L. C., and Zheng, B. (2013) Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation. Mol Cell 52, 161-172

58. Zhu, B., Zhou, Y., Xu, F., Shuai, J., Li, X., and Fang, W. (2012) Porcine circovirus type 2 induces autophagy via the AMPK/ERK/TSC2/mTOR signaling pathway in PK-15 cells. J Virol 86, 12003-12012

Footnotes

Abbreviations used in this paper: Acetyl coenzyme A carboxylase (ACC), mDC, mature dendritic cell; mTORC1 and mTORC2, mammalian target of Rapamycin complex 1 and 2; ERK1/2, extracellular signal related kinase1/2; PI3K, phosphoinositide 3-kinase; PTX, pertussis toxin, popliteal lymph node (PLN); FOXO, Forkhead box class O.

*This work was supported by grants awarded by Ministerio de Educación y Ciencia (SAF2005-00801), Ministerio de Ciencia e Innovación (SAF2008-01468), Ministerio de Economía y Competitividad (SAF2011-23890), Ministerio de Economía y Competitividad (SAF2011-23890), RIER (RETICS Program/ Instituto de Salud Carlos III) (RD08/0075) and Consejería de Educación y Empleo from Comunidad de Madrid (Raphyme, S2010/BMD-2350). PLC was supported by a FPI scholarship (Ministerio de Economía y competitividad), CGM was supported by a contract associated to grant Raphyme S2010/BMD-2350 (Consejería de Educación y Empleo. Comunidad de Madrid). LGC and JFB were supported by scholarship FPU and I3P intro, respectively (Ministerio de Educación y Ciencia). JTB and CED were recipients of JAEdoc and I3P contracts (Consejo Superior de Investigaciones Científicas-Fondo Social Europeo). CDM was partially supported fellowship FPI, conferred by the Ministerio de Educación y Ciencia (Spain) and by a contract associated to grant RD08/0075 (RIER).
CCR7 promotes inhibition of AMPK in human dendritic cells

LEGENDS TO FIGURES

Fig. 1. AMPK induces apoptosis in dendritic cells. A, (a) DCs were suspended in 10% FCS in RPMI and then incubated for 24 h either in this medium alone (-) or in this medium plus Akt inhibitor (Akti) (5 μM), AICAR (1 mM) or A769662 (25 μM). Aliquots of DCs were subjected to a Western blotting analysis with Abs against phospho-AMPKα (T172), phospho-ACC or total AMPKα. (b) Photographs taken from representative samples of the Hoechst 33342 stained DCs treated as in (a). Arrowheads indicate apoptotic cells, showing condensed or fragmented nuclei. (c) DCs were suspended in 10% FCS in RPMI and then incubated in medium alone (-) or in medium plus Akt inhibitor (Akti), AICAR or A769662, as in (a). The number represents fold-increase in the number of apoptotic DCs, determined by Hoechst 33342 staining, with respect to the control untreated DCs kept in 10% FCS in RPMI, which was considered as 1. Results shown represent the mean±SD (n=4). (d) The cells were treated or not with Akti, AICAR or A769662 as in (b). The number represents fold-increase in the number of DCs that presented DC fragmentation upon propidium iodide (PI) staining with respect to control un-treated DCs kept in 10% FCS in RPMI. Results shown represent the mean±SD (n=6). (e) The DCs were suspended in 10% FCS in RPMI and then incubated for 33 h either in this medium alone (-) or in this medium plus Akt inhibitor (Akti), AICAR or A769662 as in (a). Aliquots of DCs were subjected to a Western blotting analysis with an antibody against caspase-3. The blots were probed with an antibody against α-tubulin to show equal loading. A representative experiment out of two performed is shown. B, DCs were suspended in 0.1% BSA in RPMI and then incubated for 40 h either in this medium alone (-) or including AICAR (1 mM) or A769662 (25 μM), either in the absence (control) or in the presence of 10 μg/ml of pan caspase inhibitor z-VAD-FMK. The apoptotic DCs observed in medium alone (-) untreated with z-VAD-FMK were given an arbitrary value of 1 and the fold-increase of apoptosis in the other samples were referred to this value. Results shown represent the mean±SD (n=5). C, mDCs were nucleofected either with random siRNA (Control-siRNA) or with a siRNA specific for AMPK (AMPKα1-siRNA). (a), 36 h after nucleofection, mDCs were washed in RPMI and then an equal number of live DCs, determined by trypan blue exclusion, were subjected to a Western blotting with an anti-AMPKα antibody. To confirm equal loading, the blots were reprobed with an antibody reacting with β-actin. (b), Samples of DCs nucleofected either with Control or with AMPKα1-siRNA were washed in RPMI and then an equal number of live DCs, determined by trypan blue exclusion, were transfected to 0.1% BSA in RPMI for additional 24 h. At the end of this period, the DCs were stained with Hoechst. The number of apoptotic DCs observed in the Control siRNA nucleofected DCs were given an arbitrary value of 1, and the number of apoptotic DCs observed in AMPK siRNA transfected DCs were referred to this value. Results shown represent the mean±SD (n=3).

Fig. 2. Active AMPK may promote apoptosis by inducing translocation of FOXO1 to the nucleus and by inhibiting mTORC1. A. (a) The DCs were transfected with vector- or FOXO1-GFP and 6 h after transfection, the cells were re-suspended in 10%FCS RPMI and then either kept untreated (control) or treated with AICAR (1 mM), A769662 (25 μM) or LY294002 (100 μM) for additional 2.5 h. Subsequently, the DCs were plated onto polyornithine-coated (PON)-coated coverslips, fixed, permeabilized and stained with Hoechst 33342. The DCs were examined with a fluorescence microscope. Scale bar represents 20 μm. (b) Bar diagram representing the percentage of vector- or FOXO1-GFP transfected DCs with GFP staining concentrated in the nucleus. Results shown represent the mean±SD (n=3). B, DCs were suspended in 0.1% BSA in RPMI and then kept untreated (-) or stimulated with A769662 (25 μM) or AICAR (1 mM) for 16 h. Aliquots of the DCs were subjected to a Western
CCR7 promotes inhibition of AMPK in human dendritic cells

blot with an Ab against Bim. Blots were reprobed with an antibody reacting with β-actin to show equal loading (a representative experiment is shown). C, (a) The DCs were suspended in 0.1% BSA in RPMI and then treated (+) or not (-) for 40 h with Rapamycin (RAPA, 100 nM). DCs maintained in 10% FCS in RPMI were used as negative controls. The DCs were plated on PON-coated coverslips, fixed, stained with Hoechst and the apoptotic cells examined as indicated in Methods (see article). Results shown represent the mean±SD (n=3). (b) To confirm that RAPA inhibited mTORC1, aliquots of the control- or RAPA-treated DCs from (a), were stimulated (+) or not (-) with CCL21 (15 nM). Subsequently, the DCs were lysed and analyzed by SDS-PAGE, followed by Western blotting. The blots were analyzed with Abs against phosphorylated-4EBP1 (T37/48), phosphorylated-Akt (S473). To show equal loading, the membranes were reprobed with an Ab against Akt. D, DCs (100,000 cells), suspended in 0.1% BSA in RPMI, were stimulated for the indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phosphorylated TSC2 (T1462) and phosphorylated 4EBP1 (T37/48). To show equal loading, the membranes were reprobed with Abs against total 4EBP1. A representative experiment out of 3 performed is shown. E, The DCs were suspended in 0.1% BSA in RPMI and then kept untreated (Control) or treated with A769662 (15 nM) or AICAR (1 mM) for 60 min. Subsequently, the DCs were stimulated (+) or not (-) with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting. The blots were analyzed with Abs against phosphorylated-4EBP1 (T37/48), phosphorylated-AMPKα (T172). To show equal loading, the membranes were reprobed with an Ab against AMPKα.

Fig. 3. Stimulation of CCR7 induces phosphorylation/inhibition of AMPK. A, DCs (100,000 cells), suspended in 0.1% BSA in RPMI, were stimulated for the indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phosphorylated/inhibited AMPKα (S485). To show equal loading, the membranes were reprobed with Abs against total AMPKα. A representative experiment out of 3 performed is shown. B, DCs (100,000 cells), suspended as in (A), were stimulated with CCL21 for the indicated times and then extracted and subjected to a Western blotting with Ab against phospho-ACC (S79) and against phosphorylated/active AMPKα (T172). To show equal loading the membrane was reprobed with an Ab against total AMPKα. A representative experiment out of 3 performed is shown. C, (a) DCs, suspended as in (A), were either untreated (Control) or treated with AMPK inhibitor Compound C (20 μM) for 60 min. Control and Compound C-treated DCs were stimulated with CCL21 (15 nM) for 5 min, and subsequently, lysed and subjected to Western blot analysis with Abs against phospho-AMPKα (T172) and AMPKα. A representative experiment out of 3 performed is shown. (b) Aliquots of the Control or Compound C-treated samples, stimulated or not with CCL21, were used to analyze the activity of AMPK using the anti-phosphorylated AMPKα (S485) antibody. To show equal loading the membrane was reprobed with an Ab against total AMPKα.

Fig. 4. Activation of AMPK increases the apoptosis of dendritic cells in vitro and in the lymph nodes. A, (a) Splenic mDCs (500,000 cells) suspended in 10% FCS in RPMI were kept unstimulated (control) or stimulated for the indicated times with AICAR (1 mM) or A769662 (25 μM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phospho-AMPKα (T172), total AMPKα and β-actin. A representative experiment out of 5 performed is shown. (b) Aliquots of the Splenic DCs treated as in (a) for 2 h were fixed and stained with Hoechst 33342 to detect apoptotic DCs. The number represents the fold-increase in the number of apoptotic DCs respect to the number of apoptotic DCs observed in the controls that was considered as 1. Results represent the mean±SD (n=6 experiments). B, Splenic DCs (500,000 cells) suspended in 0.1% BSA in RPMI were stimulated for the indicated times with murine CCL19 or CCL21 (both at 15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phospho-AMPKα (S485), total AMPKα and β-actin. A representative experiment out of 5 performed is shown. C, (a) Experimental protocol. 2x10⁶ CFSE-labeled splenic DCs were injected in the footpads of recipient mice. After 36 h, the animals were injected intraperitoneally with 100 μ moles of A769662 or a similar volume of vehicle DMSO. After additional 4.5 h, mice were injected (i.v) with SR-FLIVO to stain apoptotic DCs in the LNs. After 1h, the popliteal LNs were
CCR7 promotes inhibition of AMPKα1 in human dendritic cells

extracted, fixed and subjected to two-photon analysis. (b) Representative SR-FLIVO staining displayed by CFSE-labeled DCs obtained from the LNs of animals treated either with A769662 or DMSO. The LNs of the mice were extracted and studied by two-photon microscopy as indicated in Methods. (c) The stacks of optical images of the LNs were examined with the Leica Confocal Software and the values of the Maximum Amplitude of the SR-FLIVO and CFSE channel were obtained as indicated before (see Methods). Data from 2 experiments are presented. The data are represented as maximum intensity of SR-FLIVO over maximum intensity of CFSE for each individual DC in a LN. A769662-treated animals, (74 DCs, Exp 1, 26 DCs Exp 2), DMSO vehicle-treated animals (171 DCs, Exp 1, 237 DCs, Exp 2).

Fig. 5. Signaling downstream of CCR7 regulating the phosphorylation of AMPKα1 on Serine 485. A, (a) DCs (100,000 cells) in complete medium were either kept untreated (Control) or treated with Pertussis toxin (PTX) (100 ng/ml) for 180 min. Subsequently, the DCs were washed and suspended in 0.1% BSA in RPMI. Control- and PTX-treated DCs were stimulated with CCL21 (15 nM) for 5 min and subsequently lysed and subjected to Western blotting with the Ab against phosphorylated-AMPKα1 (S485) or phosphorylated-ERK1/2 (T202/Y204 ERK1/ T185/Y187 ERK2). ERK2 levels show equal loading of the gels. A representative experiment out of 3 performed is shown. (b) DCs, untreated or pretreated with the G_{α1} inhibitor Galalin (40) for 15 min, were stimulated or not with CCL21 for 5 min, then lysed and aliquots subjected to Western blot with an Ab against phosphorylated-AMPKα1 (S485) and phosphorylated-ERK1/2 as in (a). ERK2 levels show equal loading of the gels. A representative experiment out of 3 performed is shown. B, DCs suspended in 0.1% BSA in RPMI were either left untreated (Control) or pre-treated for 60 min with (a) the PI3K inhibitor LY29402 (100 μM, 60 min) or (b) the Akt inhibitor Akti. 1,2 (5 μM). The DCs were subsequently stimulated or not with CCL21 (15 nM) for 5 min and then lysed and aliquots subjected to Western blot with the Ab against phosphorylated/inhibited AMPKα1 (S485) or against phosphorylated/active Akt1 (S473). β-actin levels show equal loading of the gels. A representative experiment out of 3 performed is shown. C, DCs (100,000 cells), suspended in 0.1% BSA in RPMI, were stimulated for the indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phosphorylated-TSC2 (T1462), phosphorylated-mTOR (S2448) or phosphorylated-4EBP1(T37/46). To show equal loading, the membranes were reprobed with Abs against total TSC2 and mTOR. D, DCs suspended in 0.1% BSA in RPMI were either left untreated (control) or pre-treated for 60 min with Akt inhibitor (Akti) (5 μM), RAPA (100 nM) or KU0063794 (Ku) (500 nM). The DCs were subsequently stimulated or not with CCL21 (15 nM) for 5 min. The DCs were then lysed and analyzed by Western blotting with Abs against phosphorylated/inactive AMPKα1 (S485), against phosphorylated/active S6K (T389) and phosphorylated/active Akt (S473). Membranes were also probed with antibodies that recognize total S6K and AMPKα.

Fig. 6. CCR7-dependent phosphorylation/inhibition of AMPK is mediated by MEK. A, DCs (100,000 cells) suspended in 0.1% BSA in RPMI were stimulated for the indicated times with CCL21 (15 nM), then lysed and analyzed by SDS-PAGE, followed by Western blotting with Abs against phosphorylated AMPKα1 (S485), MEK1/2 (S217/221), ERK1/2 (T202/Y204 ERK1/ T185/Y187 ERK2). To show equal loading, the membranes were reprobed with an Ab against AMPKα. A representative experiment out of 3 performed is shown. B, (a) DCs suspended in 0.1% BSA in RPMI were either left untreated (Control) or pre-treated with UO126 (2.5 μM, 60 min). The mDCs were subsequently stimulated or not with CCL21 for 5 min and then lysed and the aliquots subjected to Western blot with an antibody against phosphorylated/active AMPKα1 (S485) or phosphorylated-active ERK1/2 (T202/Y204 ERK1/ T185/Y187 ERK2). α-tubulin (α-TUB) levels show equal loading of the gels. A representative experiment out of 3 performed is shown. (b) Fold-increase in the phosphorylation of AMPK in control and UO126 (UO)-treated mDCs, upon stimulation with CCL21. In both control and UO126 treated DCs the degree of phosphorylation of the unstimulated DCs was given an arbitrary value of 1 and fold increase in the CCL21-stimulated mDCs was represented. (c) Similar to (b) with the difference that Fold increase-in phosphorylation of ERK1/2 was examined. C, (a) The experiments were performed as described in (b), with the only
CCR7 promotes inhibition of AMPK in human dendritic cells

difference that the DCs were treated with PD325901 (1 µM, 60 min). (b) and (c), similar to (b) and (c) in (B), with the only difference that PD325901 was used.

**Fig. 7.** CCR7-dependent phosphorylation/inhibition of AMPK is mediated by ERK. A, (a) DCs suspended in 0.1% BSA in RPMI were either left untreated (Control) or pre-treated with CAY10561 (20 µM, 2.5 h). The DCs were stimulated with CCL21 (15 nM) for 5 min and then lysed and aliquots subjected to Western blot with antibodies against phosphorylated/inactive AMPKα1 (S485), total AMPKα, phosphorylated-active ERK1/2 (T202/Y204 ERK1 / T185/Y187 ERK2) and total ERK2. A representative experiment out of 5 performed is shown. (b) Fold-increase in AMPK phosphorylation in control and CAY10561-treated mDCs, upon stimulation with CCL21. In both control and CAY10561-treated DCs the degree of phosphorylation of the unstimulated DCs were given an arbitrary value of 1 and the fold increase in the CCL21-stimulated mDCs was represented. (c) Similar to (b) with the difference that fold-increase in phosphorylation of Erk1/2 was examined. In (b) and (c), the results represent the mean±SD (n = 5 experiments). B, (a) Experiments were performed as described in (A), with the differences that FR180 (100 µM, 60 min) was used and that anti-total ERK1/2 shows equal loading of the gels. A representative experiment out of 3 performed is shown. (b) Similar to A(b), with the difference that fold-increase in AMPK phosphorylation was examined in the presence of FR180 as indicated in B(a). (c) Experiments similar to A(c) with the difference that fold-increase in phosphorylation of Erk1/2 was examined in the presence of FR180 as indicated in B(a). In (b) and (c), the results represent the mean±SD (n = 3 experiments). C, Relative number of apoptotic DCs in unstimulated (-) and CCL21-stimulated DCs (+), after treating the mDCs with Akt inhibitor (Akti), the MEK1/2 inhibitor U0126 (UO) and the ERK1/2 inhibitor CAY10561 (CAY). Results represent the mean±SD (n = 5 experiments).

**Fig. 8.** AMPKα interacts with ERK1. A, Equal number of DCs, stimulated (+) or not (-) with CCL21 (15 nM), were subjected to immunoprecipitation with anti-AMPKα antibody or with IgG control and subsequently the immunoprecipitates were separated by SDS-PAGE, followed by Western blotting with anti-ERK1 or anti-AMPKα antibodies. A lysate of DCs was used as positive control. Aliquots of the lysates used to immunoprecipitate AMPK were analyzed for Western blotting for the presence of β-actin to demonstrate equal amount of proteins immunoprecipitated (not shown). B, Interaction between ERK1 and AMPKα in mDCs was detected as fluorescent signals using the proximity ligation assay (PLA). (a) and (b) PLA negative controls performed by labeling the DCs only with (a) the anti-ERK1 or anti-AMPKα antibodies plus the anti-rabbit MINUS and the anti-Goat PLUS and (b) the anti-MEK1 antibody and the anti-rabbit MINUS and the anti-mouse PLUS probes. Normarski and nuclei stained with Hoechst 33342 are also shown. (Scale bar, 10 µm). In (a) and (b) the number of fluorescent signals per cell was also quantified. At least 40 cells per field were counted. Results represent the mean±SD (n = 3 experiments). (c) PLA fluorescent staining, indicating interaction between ERK1 and AMPKα, after CCL21 stimulation. (d) Positive control. PLA fluorescent staining between MEK1 and ERK1 upon CCL21 stimulation. Normarski and nuclei stained with Hoechst 33342 are also shown. (Scale bar, 10 µm). In (c) and (d) the number of fluorescent signals per cell was also quantified. At least 40 cells per field were counted. Results represent the mean±SD (n = 3 experiments).

**Fig. 9.** CCR7-stimulated phosphorylation-inhibition of AMPK. Stimulation of CCR7 with CCL19 or CCL21 induces Gi, Gβγ mediated activation of the kinases MEK1/2 / ERK1/2. CCR7 also induces activation of the PI3K/Akt/mTORC1/4EBP1 and S6K pathway, which promote survival in mDCs. Active AMPK induces apoptosis in mDCs by inhibiting the pro-survival effects of mTORC1 and by promoting translocation of the transcription factor FOXO to the nucleus, where it can control the expression of the pro-apoptotic Bcl2 family member Bim. Stimulation of CCR7 regulates, through the Gi,Gβγ/MEK1/2-ERK1/2 pathway (and independently of the PI3K/Akt/mTORC1pathway), the phosphorylation of the kinase AMPK on S485, which results in the inhibition of this kinase and the consequently dampening of its pro-apoptotic effects. Therefore, CCR7 promotes survival in DCS through Akt-dependent mechanisms described before and by promoting MEK/ERK dependent inhibition of AMPK.
Fig 1

A
(a) Akti AICAR A769662

- p-AMPKα (T172)
- p-ACC (S79)

AMPKα

(b) - Akti

AICAR A769662

(c) Apoptotic DCs (Hoechst) (Fold-increase)

- p=0.05
- p=0.04
- p=0.02

(d) DNA fragmentation (PI) (Fold-increase)

- p=0.016
- p=0.0070
- p=0.026

(e) - AICAR A769662

Caspase 3

α-Tub

B

Apoptotic DCs (Hoechst) (Fold-increase)

- Control
- AICAR
- A769662

ns

p=0.014
p=0.024

C

(A) Control-siRNA AMPKα-siRNA

AMPKα

β-Actin

(b) Relative number of apoptotic DCs (Hoechst)

Control-siRNA

AMPKα-siRNA

p=0.0105
Fig 2

A (a) FOXO1-GFP

| Nomarski | GFP | Hoechst | GFP |
|----------|-----|---------|-----|
| Control  |     |         |     |
| A769662  |     |         |     |
| AICAR    |     |         |     |

(b) DC with nucleolus GFP (%)

- Control
- AICAR
- A769662
- LY294002

B

| Time | A769662 | AICAR |
|------|---------|-------|
| 0 h  |         |       |
| 16 h |         |       |

- β-Actin
- Bim

C (a) % Apoptotic DCs

- 0.1%BSA RPMI
- 10%FCS RPMI
- Rapa

(b) CCL21

- Control
- Rapa

- p-TSC2 (T1462)
- TSC2
- p-4EBP1 (T37/46)
- 4EBP1

- p-Akt (S473)
- Akt

D

| CCL21 | 0 | 2 | 5 | 15 | 30 |
|-------|---|---|---|----|----|

- p-TSC2 (T1462)
- TSC2
- p-4EBP1 (T37/46)
- 4EBP1

E

| CCL21 | Control | A769662 | AICAR |
|-------|---------|---------|-------|

- p-AMPKα (T172)
- p-4EBP1 (T37/46)
- AMPKα
Fig 3

A

CCL21

0 1 2 5 10 15 30 60 120 time (min)

p-AMPKα1 (S485)

AMPKα

B

CCL21

0 2 5 10 30 time (min)

p-ACC (S79)

p-AMPKα (T172)

AMPKα

C

(a)  

Control Comp. C

p-AMPKα (T172)

AMPKα

(b)  

Control Comp. C

CCL21

- + - +

p-AMPKα1 (S485)

AMPKα
A

(a) $2 \text{ h}$

| Control | AICAR | A769662 |
|---------|-------|---------|
| p-AMPKα (T172) | | |
| AMPKα | | |
| β-actin | | |

(b) Number of apoptotic DCs (Hoechst)

| | control | AICAR | A7696662 |
|-----------------|--------|--------|-----------|
| p = 0.002 | | | |
| p = 0.031 | | | |

B

CCL19 | CCL21

| time (min) | 0 | 5 | 10 | 0 | 5 | 10 |
|------------|---|---|----|---|---|----|
| p-AMPKα1 (S485) | | | | AMPKα | | |
| β-Actin | | | |

C

(a) Injection of A7696662 or DMSO SR-FLIVO

DC (CFSE)

(b) SR-FLIVO | CFSE

Control

A769

(c)

| | | |
|---------------------|---------------------|---------------------|
| p = 4.207e-019 | | |
| p = 1.463e-038 | | |

Fig 4
**Fig 5**

A. (a) Control PTX  
   CCL21 - + - +  
   p-AMPKα1 (S485)  
   p-ERK1 (T202/Y204)  
   p-ERK2 (T185/Y187)  
   ERK2  
   (b) Control Gallein  
   CCL21 - + - +  
   p-AMPKα1 (S485)  
   p-ERK1 (T202/Y204)  
   p-ERK2 (T185/Y187)  
   ERK2

B. (a) Control LY  
   CCL21 - + - +  
   p-AMPKα1 (S485)  
   p-Akt (S473)  
   β-Actin  
   (b) Control Akti  
   CCL21 - + - +  
   p-AMPKα1 (S485)  
   p-Akt (S473)  
   β-Actin

C. CCL21  
  0 2 5 15 30 time (min)  
  p-TSC2 (T1462)  
  TSC2  
  p-mTOR (S2448)  
  p-4EBP1 (T37/46)  
  mTOR

D. Control Akti Rapa Ku  
   p-AMPKα1 (S485)  
   AMPKα  
   p-S6K (T389)  
   S6K  
   p-Akt (S473)
CCL21

\[ t \text{ (min)} \]

0.5 1 2 2.5 5 10

p-AMPK\(\alpha_1\) (S485)
p-MEK1/2 (S217/221)
p-ERK1 (T202/Y204)
p-ERK2 (T185/Y187)

AMPK\(\alpha\)

\(p=0.0149\)

\(p=0.0435\)

\(p=0.0006\)

\(p=0.0213\)

\(p=0.0435\)

\(p=0.0149\)

Fig 6
Fig 8
**Fig 9**

- CCL19
- CCL21
- CCR7

**Survival**

- PI3K → Akt → mTORC1
- MEK1/2 → ERK1/2

**Apoptosis**

- AMPK
- FOXO
- Bim

**Proteins and Phosphorylation**

- 4EBP1
- S6K